Achilles Therapeutics plc
Achilles Therapeutics plc (ACHL) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
achl · pe ratio · data through Dec 31, 2023
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Achilles Therapeutics plc (ACHL) measures how much investors pay for each dollar of the company's trailing earnings. ACHL's current PE ratio of N/A is calculated by dividing its stock price of $1.48 by its TTM earnings per share of -$1.74.
Source: FMP · /ratios-ttm · /analyst-estimates · 2023-12-31
PE Ratio History
2018 – 2023 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Achilles Therapeutics plcYou ACHL | $61M | N/A | — | -$1.74 |
 AlloVir, Inc. ALVR | $49M | N/A | — | -$0.28 |
 Heat Biologics, Inc. HTBX | $61M | N/A | — | -$1.41 |
 Kronos Bio, Inc. KRON | $54M | N/A | — | -$1.43 |
 Quince Therapeutics, Inc. QNCX | $6M | N/A | — | -$16.76 |
 Rein Therapeutics Inc. RNTX | $25M | N/A | — | -$1.96 |
 Reneo Pharmaceuticals, Inc. RPHM | $61M | N/A | — | $0.00 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2023-12-31Latest FY2023 | — | $-1.74 | — | |
2022-12-31 FY2022 | — | $-1.82 | — | |
2021-12-31 FY2021 | — | $-2.13 | — | |
2020-12-31 FY2020 | — | $-0.82 | — | |
2019-12-31 FY2019 | — | $-20.50 | — | |
2018-12-31 FY2018 | — | $-12.71 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Achilles Therapeutics plc (ACHL) measures how much investors pay for each dollar of the company's trailing earnings. ACHL's current PE ratio of N/A is calculated by dividing its stock price of $1.48 by its TTM earnings per share of -$1.74.
Frequently asked questions
ACHL pe ratio · 6 questionsACHL's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.48 and TTM EPS of -$1.74. Data sourced from Financial Modeling Prep via ACHL's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Achilles Therapeutics plc SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09